Single Dose of Ceftriaxone Shields Brain Injury Patients from Ventilator-Associated Pneumonia
22 Jan 2024 • Patients with acute brain injury are at high risk of ventilator-associated pneumonia (VAP). The benefit of short-term antibiotic prophylaxis remains debated.
In the recently published PROPHY-VAP study, a single IV dose of ceftriaxone (2g) administered within 12 hours of tracheal intubation significantly decreased the incidence of early VAP (14% vs. 32% in the placebo group), occurring from the 2nd to the 7th day of ventilation.
On the basis of these findings published in The Lancet, researchers recommend that an early, single dose of ceftriaxone be included in all bundles for the prevention of VAP in patients with brain injury who require mechanical ventilation.
Source: The Lancet | Read full story